Early clinical stage therapeutics company developing BRY101, a metabolic modulator engineered to increase intracellular NAD, impacting mitochondrial dysfunction, neuroinflammation and oxidative stress. BRY101 impacts multiple pathways simultaneously, breaking away from the traditional single-target drug development model. This strategy is designed to address the complex mechanisms involved in neurodegenerative and neuromuscular disorders.
Bryleos: More Life While Living
Company Details
- Employees
- 8
- Founded
- -
- Address
- 207 North Boone Street,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.bryleos.com
- Keywords
- neuroscience, Parkinson's, Alzheimer's, Multiple Sclerosis, neuropsychiatry, Metabolic Disorder, ALS.
- HQ
- Johnson City, Tennessee
Bryleos Questions
Bryleos's website is http://www.bryleos.com
Bryleos's LinkedIn profile is https://www.linkedin.com/company/bryleos
Bryleos has
8 employees.
View email and phone details for 8
employees at Bryleos.
Bryleos's industry is
Biotechnology Research
Bryleos's categories are Biotechnology Research
Bryleos's founding year is 2021
